secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXOZYMES INC. (EXOZ)
CIK:        0002010788
Form:       8-K
Filed at:   2025-12-12T23:59:59+00:00
Accession:  0001493152-25-027327
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

eXoZymes achieves 100× scale-up of NCT production with >99% feedstock conversion
--------------------------------------------------------------------------------

- Scaled NCT production 100-fold using proprietary exozyme cell-free platform, achieving >99% conversion from feedstock to product.
- Batch executed under partner-operated conditions by Cayman Chemical, demonstrating process robustness and transferability.
- CEO Michael Heltzen calls milestone an inflection point for cell-free enzyme-driven biomanufacturing.
- Additional technical details and NCT extraction results expected in early 2026 after downstream analysis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2010788/000149315225027327/0001493152-25-027327-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2010788/000149315225027327/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-027327

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer